AI-Driven Biomarkers and Early Cancer Detection: Where Multi-Cancer Blood Tests Stand in 2026
How AI-driven biomarkers power multi-cancer early detection blood tests, what PATHFINDER 2 and NHS-Galleri showed, 2026 FDA status and what is unproven.
-
-
Fluorescent LFA vs. Traditional Testing: A Guide for Healthcare Systems
How fluorescent lateral flow compares with central-lab and visual rapid tests for cancer biomarkers: speed, accuracy, cost, workflow and what to validate.
